Skip to content
‹ Back to IndustriesHealthcare

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · · PhilipsQ3 2026 EarningsMedical DevicesDiagnostic Imaging
Share
Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Key takeaways

01

Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.

02

Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.

03

Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by its Diagnosis & Treatment segment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its full-year outlook. Separately, Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter.

Orders and sales by segment

Order intake growth matched the 8% posted a year earlier. According to Investing.com's account of the earnings call, management said Diagnosis & Treatment orders grew nearly 20%, with double-digit growth in both Image Guided Therapy and Precision Diagnosis, while Connected Care order intake declined by a mid-single-digit percentage against more than 20% growth in the prior-year period, which it attributed to the timing of large orders. The equipment order book stands at about 40% of revenue.

Sales told a slightly different story. Diagnosis & Treatment comparable sales were flat at EUR 2,085 million, as growth in Image Guided Therapy was offset by a decline in Precision Diagnosis that Philips attributed to the phasing of ultrasound sales and lower sales in China, as it had flagged at the second quarter. Connected Care sales rose 5% on a comparable basis to EUR 1,176 million, with growth in all businesses. Personal Health rose 8% to EUR 953 million. Adjusted EBITA margins improved in all three segments: 12.3% in Diagnosis & Treatment, 13.3% in Connected Care and 17.7% in Personal Health.

Philips reported EUR 170 million of net productivity savings in the quarter and EUR 427 million year to date, and said it remains on track for EUR 1.5 billion under its 2026 to 2028 program. Free cash flow was EUR 384 million, up from EUR 172 million a year earlier, on operating cash flow of EUR 544 million. The company also placed a EUR 650 million green bond due 2034 that was 2.7 times oversubscribed.

The Respironics agreement in principle

In its results statement, Philips said Respironics reached an agreement in principle with the DOJ to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. The settlement is subject to finalization of the relevant documentation, and payment is expected in the first quarter of 2027. The EUR 288 million provision was the main reason income from operations fell to EUR 165 million from EUR 330 million a year earlier, and net income was EUR 28 million against EUR 187 million. Philips also noted that the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the company's affairs in connection with the recall.

Chief executive Roy Jakobs called the agreement in principle an important step and said the company continues to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The 2026 outlook assumes the DOJ payment in the first quarter of 2027 and excludes other ongoing Respironics-related proceedings, including the investigation by US state attorneys general.

Outlook

Philips reiterated guidance for 3% to 4.5% comparable sales growth, an adjusted EBITA margin of 13.5% to 14.0% including a US tariff refund benefit of about 1%, and free cash flow of EUR 1.5 billion to EUR 1.7 billion including a net tariff refund benefit of about EUR 200 million. The outlook includes currently known tariffs. Shares rose about 5% in US premarket trading after the release, Investing.com reported.

What it means for hospitals and device makers

The order numbers are the signal for the imaging and interventional market. Near-20% order growth in Diagnosis & Treatment, with strength in both image-guided therapy and diagnostic imaging, points to hospitals continuing to commit capital to cath labs, imaging suites and ultrasound even as China procurement and tariffs weigh on the near term. The Connected Care order dip is one quarter and tied to large-order timing, by the company's account. For suppliers and integrators, an order book at 40% of revenue means a visible installation pipeline into 2027.

Featured companies

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Four software renewal questions to help get HbA1c to the dental chair

Four software renewal questions to help get HbA1c to the dental chair

Dr. Deepashree Rajendraprasad, a dentist turned hospital business intelligence developer, gives dental practices four questions for software vendors at contract renewal. They cover HL7 FHIR APIs, health information exchange access, SNODENT terminology and electronic referrals. The standards already exist. The payoff shows up chairside in anticoagulant screening, diabetes-guided periodontal care and bisphosphonate surgical planning.

  • 01The HbA1c a dentist asks a patient to remember already sits as a structured field in a hospital data warehouse; getting it to the chair starts with what a practice asks its software vendor.
  • 02Two of the five FHIR resources most relevant to dentistry, Patient and Observation, belong to the normative core of FHIR Release 4, where future changes are meant to stay backward compatible.
  • 03At renewal, ask vendors specifics: which FHIR resources they expose, whether they can query the regional HIE, whether they code in SNODENT, and whether they support structured referrals.

Nov 18, 2026

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

Johns Hopkins' Ritu Agarwal wants hospitals to measure a baseline before scaling AI

A Google Cloud survey found that only 30% of healthcare organizations have scaled advanced or agentic AI across their operations. Johns Hopkins professor Ritu Agarwal says health systems need a measured baseline, clinician-led workflow design and representative data before they scale. Small pilots hide the rest.

  • 01A 200-person pilot answers whether a tool works; how it behaves on another hospital's patients and what it costs at full volume mostly show up after the pilot ends.
  • 02Just 30% of healthcare organizations said they’ve scaled advanced or agentic AI across operations, according to a Google Cloud survey of 250+ healthcare executives.
  • 03The sharper pre-pilot question: which disease condition, which baseline metric and what projected cost at full volume will this tool be judged against?

Nov 18, 2026

Sterile processing deviations become the norm without stop-and-document rules

Sterile processing deviations become the norm without stop-and-document rules

Advanced Sterilization Products' Tamara Beeler told Censis Technologies' CtUC 2026 audience that sterile processing deviations harden into norms when departments don’t stop, escalate and document them. She connects ANSI/AAMI ST108:2023 water categories, daily cleaning verification, loaner-tray refusal when sets arrive late or lack IFUs, and root cause analysis when rework repeats on the same device.

  • 01ANSI/AAMI ST108:2023 turned water quality for instrument reprocessing into an enforceable standard; AAMI's earlier TIR34 was guidance with no enforcement behind it.
  • 02Some facilities require loaner trays 48 hours before a case, and ASP's Tamara Beeler says a technician at any level can refuse one that arrives late, undocumented or dirty.
  • 03Rework that returns on the same device is the point at which Beeler wants a root cause analysis opened, with the record kept in the instrument tracking system.

Nov 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512